U.S. FDA postpones Schering panel for melanoma

WASHINGTON (Reuters) - A U.S. Food and Drug Administration advisory panel to review the use of Schering-Plough Corp's (SGP.N) Pegintron drug to treat serious skin cancer has been postponed, the company said on Monday.

A group of FDA advisors had been expected to meet on Wednesday to review expanded use of the widely-used hepatitis C drug against melanoma, the deadliest skin cancer.

A Schering-Plough spokeswoman said the FDA was seeking clarification of existing data and no new date had been set.

(Reporting by Kim Dixon, editing by Gerald E. McCormick)